Sector Expert: Anita Dushyanth

Zacks Investment Research

Image: Anita Dushyanth

Anita Dushyanth is a medical technology and devices analyst with Zacks Investment Research. Prior to joining Zacks, she has worked as a researcher in the field of bioengineering at the University of California, Los Angeles (UCLA) for more than 10 years. Her expertise includes research that delves into design and development of medical compliant devices, biomechanics of the human body, degenerative disease progression and quantitative image analysis and optimization. She has been a peer reviewer and editor for a number of journals in the field of biomedical engineering. Prior to that, Dushyanth worked as a researcher at the department of radiology and biomedical imaging at the University of California, San Francisco (UCSF). She has completed the research work for a doctorate in bioengineering from UCLA. She holds a master's degree in biomedical engineering from Wright State University in Ohio and a bachelor's degree in instrumentation engineering from the University of Madras, India.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • Biota Pharmaceuticals Inc.
  • ChroMedX Corp.
  • Cynapsus Therapeutics Inc.
  • Spectral Medical Inc.
  • Theralase Technologies Inc.


Recent Interviews

How to Engineer a Strong Portfolio with Medtech and Biotech: Zacks' Anita Dushyanth (11/11/15)
Beakers

Zacks Small-Cap Research analyst Anita Dushyanth is a bioengineer with an R&D background, which comes in handy as she researches up-and-coming companies in the medtech and biotech sectors. In this interview with The Life Sciences Report, Dushyanth focuses on four small- and micro-cap specialty pharma and device names with engineering tie-ins, and she expects all to produce exciting results for investors.

Three Biotech Investment Ideas that Disrupt and Diversify: Anita Dushyanth (9/25/14)
laserbeam580

Good management. Promising therapies in the pipeline. Marketed products that bolster the bottom line. Investors crave these bread-and-butter qualities in small-cap biotech and medtech companies. Anita Dushyanth of Zacks Investment Research relies on the staples, but also looks for something special, something that disrupts. In this interview with The Life Sciences Report, Dushyanth describes several small companies that have spiced up their offerings.

Recent Quotes

"BOTA is developing direct acting antiviral drugs for treating respiratory infections in at-risk patients with limited therapeutic options."

— Anita Dushyanth, Seeking Alpha (2/9/16)
more >

"We are initiating coverage on BOTA with a Buy rating."

— Anita Dushyanth, Zacks Small-Cap Research (1/5/16)
more >

"CTH exited Q3/15 with a solid cash balance of roughly $82M."

— Anita Dushyanth, Zacks Small-Cap Research (11/17/15)
more >

"CYNA now boasts a solid balance sheet with a cash balance of roughly $110M."

— Anita Dushyanth, Zacks Small-Cap Research (8/20/15)
more >

"We are very positive on TLT's technology. It's very promising."

The Life Sciences Report Interview with Anita Dushyanth (9/25/14)
more >

"TLT's Photo Dynamic Therapy technology showed promising results for the treatment of cancer in animal models."

— Anita Dushyanth, Zacks Small-Cap Research (9/3/14)
more >

"TLT plans continued TLC-1000 sales for the remainder of 2014."

— Anita Dushyanth, Zacks Small-Cap Research (6/5/14)
more >

"We have initiated coverage on TLT with an Outperform rating."

— Anita Dushyanth, Seeking Alpha (5/9/14)
more >



Due to permission requirements, not all quotes are shown.